Avadel Pharmaceuticals
Clinical trials sponsored by Avadel Pharmaceuticals, explained in plain language.
A biopharmaceutical company focused on central nervous system disorders.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New nightly pill aims to tame daytime sleepiness in rare sleep disorder
Symptom relief CompletedThis study tested a once-nightly extended-release form of sodium oxybate (FT218) in 157 adults with idiopathic hypersomnia, a condition causing excessive daytime sleepiness despite adequate sleep. Participants were already on stable doses of stimulants or other alerting agents. T…
Phase 3 • Sponsor: Avadel • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
New sleep drug shows promise for narcolepsy patients
Symptom relief CompletedThis study followed 71 adults with narcolepsy who started taking LUMRYZ, a medication for excessive daytime sleepiness. Over 4 months, participants filled out questionnaires about their symptoms, how they felt about the drug, and their quality of life. The goal was to see if LUMR…
Sponsor: Avadel • Aim: Symptom relief
Last updated Jun 27, 2026 09:04 UTC
-
New Once-Nightly pill could simplify narcolepsy treatment
Symptom relief CompletedThis study tested a new once-nightly medication called FT218 for people with narcolepsy who experience excessive daytime sleepiness and sudden muscle weakness (cataplexy). It included 184 participants, some already on a twice-nightly medication and some new to treatment. The goal…
Phase 3 • Sponsor: Avadel • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC